Offloading Biosimilars To Biocon ‘First Step’ Towards Viatris’ $9bn Target

Viatris On ‘Clear Path’ To Building In Generics And Complex Generics

 
• By Dean Rudge
  
Target
Viatris is targeting $9bn of gross proceeds • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business